BACKGROUND: Guidelines recommend primary percutaneous coronary intervention (PCI) in patients with ST-segment-elevation myocardial infarction (STEMI) presenting ≥12 hours of symptom onset in the presence of ongoing ischemia. However, data supporting this recommendation are limited. We evaluated the effect of primary PCI on reperfusion success, using cardiac magnetic resonance, in STEMI patients with signs of ongoing ischemia presenting 12 to 72 hours after symptom onset compared with STEMI patients presenting <12 hours. CONCLUSIONS: STEMI patients with signs of ongoing ischemia treated with primary PCI 12 to 72 hours after symptom onset had less myocardial salvage and developed larger infarcts. However, a large proportion achieved substantial myocardial salvage indicating a benefit from primary PCI in late-presenting patients.
T imely reperfusion with percutaneous coronary intervention (PCI) within 12 hours of symptom onset is currently the treatment of choice in ST-segmentelevation myocardial infarction (STEMI).
1,2 However, 8% to 40% of all STEMI patients may present later than 12 hours after symptom onset 3 ; a patient group commonly designated as late presenters. According to current guidelines, late presenters are divided in unstable patients with signs of ongoing ischemia (ongoing pain or electrocardiographic [ECG] evidence of ongoing ischemia) and stable asymptomatic patients. Primary PCI is recommended in unstable late presenters, whereas routine PCI should only be considered in stable STEMI patients presenting 12 to 48 hours after symptom onset. 1 Clinical trials on late presenters treated with catheterbased revascularization have shown conflicting results, [4] [5] [6] [7] whereas imaging studies have suggested a beneficial effect of primary PCI in STEMI patients presenting up to 72 hours after symptom onset. [8] [9] [10] Common to these studies is that either stable or both stable and unstable late presenters were included, and thus it is uncertain whether stable patients blunt any additional benefit from an acute revascularization strategy in the unstable subset of patients. Additionally, the 12-hour limit is originally based on a combination of fibrinolysis being unable to reduce mortality in late-presenting STEMI patients 11, 12 and on animal models reporting loss of all jeopardized myocardium before 12 hours of coronary occlusion. 13 However, data on the 12-hours limit is inadequate in the modern era of primary PCI.
Cardiac magnetic resonance (CMR) imaging accurately assess infarct size, 14 myocardial salvage, 15 left ventricular (LV) function, 16 and microvascular obstruction (MVO). 17 These are all associated with mortality and development of heart failure, 18, 19 and CMR can thus be used to evaluate the benefit from PCI and reperfusion success.
The aim of the present study was to evaluate the effect of primary PCI in STEMI patients with signs of ongoing ischemia presenting 12 to 72 hours after symptom onset compared with STEMI patients presenting <12 hours after symptom onset.
METHODS

Study Design and Population
Between May 2015 and January 2017, all unstable STEMI patients ≥18 years of age with symptom duration of 12 to 72 hours, hospitalized and treated with primary PCI at Rigshospitalet, Copenhagen University Hospital, Denmark were prospectively screened for inclusion. Rigshospitalet is the largest PCI center in Denmark covering 2.6 million citizens (45% of the Danish population). Based on medical history, the clinical presentation, and ECG, the PCI operator categorized late presenters as stable or unstable. Instability was defined as evidence of ongoing ischemia, ongoing or recurrent pain or ongoing or recurrent pain combined with symptoms or signs of shock, heart failure, or malignant arrhythmias according to guidelines. 1 All patients had ongoing pain at presentation. STEMI was defined as ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle branch block. As comparison, data on STEMI patients treated <12 hours after symptom onset were collected from participants in the DANAMI-3 (Third Danish study on Optimal Acute Treatment of Patients with ST-segmentElevation Myocardial Infarction) that has previously been described. 20 We included DANAMI-3 participants recruited at Rigshospitalet, Copenhagen University Hospital, Denmark where CMR was performed. Previous myocardial infarction in the infarct-related artery, renal insufficiency (estimated glomerular filtration rate <30 mL/min), pacemaker, chronic atrial fibrillation, previous coronary artery bypass grafting, and potential pregnancy constituted the exclusion criteria of all participants included in the present study.
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. All participants provided written informed consent, and the trial was performed in accordance with the declaration of Helsinki. The study protocol was approved by a regional ethics committee in Copenhagen, Denmark (protocol number. H-1-2014-124), by the Danish Data Protection Agency (case file number: 30-1451) and by an institutional review committee. All data were prospectively collected and electronically stored at the Clinical Trial Unit of Rigshospitalet, Copenhagen University Hospital, Denmark. DANAMI-3 was registered at https://www.clinicaltrials.gov (unique identifiers: NCT01435408 and NCT01960933).
Cardiovascular Magnetic Resonance Imaging
The CMR protocol and image analyses of all patients were identical. Participants without contraindications underwent an in-hospital CMR during the index admission and a
WHAT IS KNOWN
• Timely reperfusion with percutaneous coronary intervention within 12 hours of symptom onset is first-chose treatment in ST-segment-elevation myocardial infarction (STEMI).
• Up to 40% of all patients with STEMI present later than 12 hours after symptom onset.
• The effect of primary percutaneous coronary intervention in STEMI patients with signs of ongoing ischemia presenting 12 to 72 hours after symptom onset is unknown.
WHAT THE STUDY ADDS
• Substantial myocardial salvage can be achieved in patients with STEMI beyond 12 hours of symptoms.
• Duration from symptom onset to percutaneous coronary intervention is not able to identify a specific time limit as a cutoff point for offering STEMI patients with clinical signs of ongoing ischemia primary angioplasty.
follow-up CMR 3 months later. The myocardial area at risk (AAR) was assessed on the in-hospital examination using a T2-weighted tau inversion-recovery sequence (Material in the Data Supplement). 21 LV volumes and function were assessed on both examinations using steady-state free precession cine images. Myocardial infarct size was assessed on the delayed contrast-enhanced images obtained after intravenous administration of 0.1 mmol/kg body weight gadolinium-based contrast (Gadovist, Bayer, Schering, Berlin, Germany) using an ECG-triggered inversion-recovery sequence (Material in the Data Supplement).
14 Final infarct size was obtained on the follow-up CMR. All scans were performed on a 1.5T scanner (Siemens, Erlangen, Germany) using a 6-channel body-array coil, and all images were obtained in the short-axis plane covering the entire LV (8 mm slices without interpolated gap).
All images were analyzed by a reader blinded to all clinical data and a second reader reviewed all analyses. In case of major discrepancies, the analyses were discussed and adjusted until consensus was reached. CVI42 (Circle Cardiovascular Imaging Inc, Calgary, Canada) was used for all analyses. LV mass, volumes, and function were measured incorporating the papillary muscle in the LV cavity. AAR and infarct size were identified using the signal intensity of normal myocardium+2 SD and 5 SD, respectively. 22, 23 MVO was visualized as hypointense areas in the contrast-enhanced myocardium and it was manually measured on the in-hospital CMR. 19 Finally, salvage index was calculated as (AAR-final infarct size/AAR). 15 Interobserver reproducibility was assessed in 20 randomly chosen DANAMI-3 patients and expressed as mean difference: 0.1±2% for infarct size, 1±2% for AAR, and 0.5±4% for LV ejection fraction (LVEF).
24
End Points
The primary end point was myocardial salvage index. Secondary endpoints were final infarct size, presence of MVO, and LV function. In addition, we identified the number of patients obtaining a large salvage index (≥0.50) as it previously has been shown that a salvage index <0.50 is strongly associated with poor clinical outcome. 25 
Statistical Analysis
Categorical variables were presented as frequencies and percentages and compared using χ 2 or Fisher exact test. Continuous variables were tested for normality, and differences were assessed using Student t test or Mann-Whitney U test accordingly. Linear regression analyses between symptom onset to primary PCI as a continuous variable and salvage index, infarct size, and LV function were performed. The association between late-presenting patients and the primary, as well as secondary end points, were adjusted for potential confounders by including any baseline variable with P<0.1 for differences between the groups in multiple regression analyses. In addition, the effect of symptom onset to primary PCI on infarct size was evaluated in a linear regression analysis, adjusting for AAR. The assumptions for general linear models were assessed and deemed valid unless otherwise stated. A prespecified subgroup analysis of the primary end point in patients presenting with Thrombolysis In Myocardial Infarction (TIMI) flow pre-PCI 0/1 versus 2/3 was performed. Furthermore, a receiver operating characteristic analysis was done to characterize the ability of symptom onset to primary PCI to predict a myocardial salvage index ≥0.50. All analyses were performed using SPSS software version 23.0 (SPSS Inc, Chicago, IL). A P value <0.05 was considered statistically significant for all analyses.
RESULTS
Between May 2015 and January 2017, 221 late presenters were screened for inclusion, 87 were included and 58 (67%) underwent CMR examination during index hospitalization, at follow-up or at both time points (Figure 1 ). In total, 1620 patients were included in the DANAMI-3 trial at Rigshospitalet, Copenhagen University Hospital, Denmark of which 807 (50%) underwent CMR examinations. The trial profile is shown in Figure 1 . The median duration from symptom onset and primary PCI to the in-hospital CMR was 1 (interquartile range [IQR], 1-1) day and 1 (IQR, 1-1) day for patients treated <12 hours and 2 (IQR, 1-2) days and 1 (IQR, 1-1) day for patients treated 12 to 72 hours after symptom onset (P<0.001 and P=0.400). All patients underwent in-hospital CMR within 7 days of symptom onset. The median duration from primary PCI to the follow-up CMR was 92 (IQR, 89-96) days and 96 (IQR, 91-100) days for patients treated <12 and 12 to 72 hours after symptom onset, respectively (P<0.001). Baseline patient characteristics and PCI procedural data are shown in Tables 1 and 2 . Late presenters more often presented with an anterior infarction, TIMI flow pre-PCI 0/1, and were more likely to have a high Killip class during admission. In addition, there were significant differences in the use of antiplatelet therapy, glycoprotein IIb/IIIa inhibitors, and bivalirudin. Finally, a greater proportion of late presenters was treated through a radial vascular access, while patients treated <12 hours more often underwent thrombus aspiration.
Patients treated 12 to 72 hours after symptom onset had larger final infarct size and lower LVEF, despite an equal AAR (Table 3) . Accordingly, myocardial salvage index was significantly smaller in the late-presenting patients. Adjusting for AAR in a linear regression analysis, showed a significant association between primary PCI 12 to 72 hours after symptom onset and final infarct size (P=0.017), and there was no interaction with AAR (P=0.921). In addition, late presenters had a higher incidence of MVO (Table 3 ). The association between infarct size, myocardial salvage index, MVO, LVEF, and PCI treatment 12 to 72 hours after symptom onset remained statistically significant in multivariable models (Table 4 ).
In the total study cohort, increasing delay from symptom onset to primary PCI was associated with increasing infarct size and decreasing myocardial salvage index and LVEF (Figure 2) . However, all correlations were weak with fairly low R 2 values. Salvage index varied from 0.0 to 1.0 in both treatment groups, and substantial myocardial salvage (salvage index ≥0.50) was observed in 65% of the late presenters compared with 75% of patients treated <12 hours (P=0.146; Figure 3 ). In addition, area under the curve for symptom onset to PCI as a predictor of a myocardial salvage index ≥0.50 was poor (0.58 [95% CI, 0.53-0.63]; P<0.001).
Among patients with pre-PCI TIMI 0/1 flow myocardial salvage index was 0.58 (IQR, 0.44-0.71) in patients treated within 12 hours after symptom onset versus 0.54 (IQR, 0.38-0.69) in patients treated 12 to 72 hours after symptom onset (P=0.338). In patients with TIMI flow pre-PCI 2/3 the myocardial salvage was 0.81 (IQR, 0.50-0.92) and 0.79 (IQR, 0.65-0.94), respectively (P=0.719). There was no interaction between symptom onset to primary PCI and TIMI flow pre-PCI (P=0.655).
DISCUSSION
To assess the effect of primary PCI in patients presenting 12 to 72 hours after symptom onset, we examined CMR data from 58 late presenters with similar analyses from a cohort of 807 patients treated with primary PCI within 12 hours of symptom onset. We found that late presenters with signs of ongoing ischemia, despite comparable AAR, had larger infarct size, smaller myocardial salvage index, more MVO, and a resulting lower LVEF compared with STEMI patients presenting <12 hours. However, a large proportion of the late-presenting patients achieved substantial myocardial salvage, and the duration from symptom onset to PCI could not predict the effect of primary PCI on myocardial salvage. Late presenters also demonstrated a substantial recovery of stunned myocardium as indicated by the increase in LVEF during a 3-month period. In addition, our analyses of LV outcome as a function of symptom onset to PCI were not able to identify a specific time limit as cutoff point for offering STEMI patients primary PCI.
Several trials have evaluated the effect of PCI in STEMI patients presenting ≥12 hours after symptom onset. [4] [5] [6] [7] [8] [9] [10] The BRAVE-2 trial (Beyond 12 Hours Reperfusion Alternative Evaluation 2) found a reduction in infarct size and a trend towards improved clinical outcome in patients treated with primary PCI compared with conservative treatment in asymptomatic STEMI patients presenting 12 to 48 hours after symptom onset. 8, 26 Whereas the OAT (Occluded Artery Trial) found no beneficial effect of subacute PCI in stable patients treated 3 to 28 days after presentation. 6 However, BRAVE-2 and OAT are hardly comparable, as the patients underwent angioplasty at 2 very different time points from symptom onset (a median of <24 hours versus 8 days). Imaging and clinical studies have reported results similar to BRAVE-2, with a reduction in myocardial damage or improved clinical outcome after primary PCI in patients with STEMI presenting 12-72 hours after symptom onset. 7,9,10 All together, these results have led to the recently updated guidelines to recommend primary PCI in STEMI patients presenting ≥12 hours after symptom onset with symptoms or signs of ongoing ischemia. 1 However, with the exception of BRAVE-2, all trials addressed a combination of stable and unstable late-presenting STEMI patients making it difficult to distinguish between the true outcome among unstable and stable patients. A recent study reported a myocardial salvage index of 0.27 in late-presenting STEMI patients treated with primary PCI 12 to 48 hours after symptom onset, 10 which is less than the present report. Importantly, however, 50% of the included patients in the study by Stiermaier et al 10 were stable at the time of presentation, suggesting they were beyond treatment effect with irreversibly injured myocardium. Symptomatic late presenters may benefit from an acute invasive therapy as symptoms, such as chest pain indicate viable myocardium. 1 On the contrary, as a consequence of nonviable myocardium, the cessation of symptoms may indicate that the therapeutic window for acute intervention has closed.
This study is the first to report that STEMI patients presenting ≥12 hours of symptom onset with signs of ongoing ischemia benefit from an acute coronary intervention. Although, late presentation ≥12 hours after symptom onset undoubtedly is associated with an increased risk of an adverse outcome partly because of larger myocardial damage 18, 19 our findings indicate a benefit from primary PCI in STEMI patients presenting ≥12 hours with signs of ongoing ischemia. Because the effect of primary PCI in unstable late presenters has not been well evaluated and the evidence is weak, this study adds important information. In this context, the risk of bias in the present study should be recognized. Unstable patients presenting 12 to 72 hours after symptom onset were included based on the indication of primary PCI, and because this population a priori was hypothesized to benefit the most from primary PCI. Furthermore, CMR measurements constituted the end point, and being a cumbersome investigation, the use of CMR includes a risk of excluding high-risk patients. 27 Whether the effect determined by CMR translates into a clinical benefit remains to be shown. However, it would be unethical to conduct a study, where symptomatic late presenters are randomized to primary PCI, subacute PCI, or no PCI, and data on clinical outcome in late presenters with symptoms or signs of ongoing ischemia must come from observational trials.
Myocardial salvage and infarct size may in addition to duration of ischemia be affected by periprocedural events, such as distal embolization, no-reflow phenomenon, or lethal reperfusion injury. It could be speculated that the risk of distal embolization and no-reflow increases in late presenters as the thrombotic occlusion of the coronary artery consolidates over time, 28 which is supported by increasing MVO among the late presenters. However, as infarct size increases with the duration of ischemia less myocardium is exposed to the risk of lethal reperfusion injury. 29 Nevertheless, as a common effect of primary PCI, our study demonstrates a favorable outcome in patients presenting ≥12 hours after symptom onset given presence of ongoing ischemia.
Experimental trials report loss of all jeopardized myocardium well before 12 hours of coronary occlusion. 13 However, major differences between human STEMI studies and animal experiments are the certainty and duration of the coronary occlusion. In animal models, the coronary occlusion is stationary, while the occlusion in STEMI patients may be intermittent with periods of recanalization. 3 Furthermore, a minimal blood flow in the infarct-related artery combined with preformed collateral vessel might maintain sufficient blood supply to avoid total necrosis and preserve viable myocardium. Finally, patients may not be able to recall the exact time of symptom onset, and preinfarction angina may have preconditioned the myocardium leading to cardioprotection and salvage of myocardium. 30 Nevertheless, TIMI flow pre-PCI is independently associated with myocardial damage, 25 and the duration of ischemia may have the biggest impact if the coronary blood flow is totally occluded. However, although more late presenters developed MVO and achieved less myocardial salvage, looking at both TIMI pre-PCI 0/1 and 2/3, there was still a substantial effect of primary PCI ≥12 hours of symptom onset. Knowledge about time limits in patients with STEMI cannot be translated from fibrinolysis to primary PCI or from animal models to humans but have to be generated from real life studies.
Limitations
The late-presenting group was considerably smaller than the group of patients treated <12 hours, and the trial participants were recruited with a time interval of 3 years leading to significant differences in the drug choice for antiplatelet therapy and vascular access site. However, our results remained statistically significant in multivariable models, adjusting for any differences between groups. Furthermore, to identify ischemic instability, it would have been informative to formally analyze ST-segment dynamics prior and in relation to the PCI procedure, however, data were not available.
Myocardial edema may be dynamic within the first few days after a myocardial infarction, 31 which may have affected our results as duration from onset of ischemia to CMR may potentially impact the assessment of AAR. However, as AAR was similar in the 2 groups this bias seems negligible in our study. Furthermore, the TIMI flow rates were reported by the PCI operators with a risk of overestimating the number of patient with TIMI flow 3 post-PCI. Finally, the present study contains a risk of patients recall bias regarding symptom onset as a coronary occlusion may be preceded by preinfarction angina. Observational trials regarding delay from symptom onset to treatment should always be interpreted with caution because of risk of survivor-cohort effect.
Conclusions
STEMI patients with signs of ongoing ischemia treated with primary PCI 12 to 72 hours after symptom onset had less myocardial salvage and developed larger infarcts. However, a large proportion achieved substantial myocardial salvage indicating a benefit from primary PCI in late-presenting patients.
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